Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael N Pollak

Showing results (61-70 of 175) with videos related to

Pageof 18
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 10, 2010
Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective studyLorelei A Mucci, Jennifer R Stark, Michael N Pollak, et al.
Breast Cancer Research and Treatment|October 23, 2012
Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, growth hormone, and mammographic density in the Nurses' Health StudiesMegan S Rice, Shelley S Tworoger, Bernard A Rosner, et al.
International Journal of Cancer|May 18, 2010
Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004Katharina Nimptsch, Elizabeth A Platz, Michael N Pollak, et al.
Gynecologic Oncology|August 25, 2009
BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamideMarie-Claude Beauchamp, Ariane Knafo, Amber Yasmeen, et al.
Cancer Research|October 9, 2012
Carbon source and myc expression influence the antiproliferative actions of metforminShiva Javeshghani, Mahvash Zakikhani, Shane Austin, et al.
International Journal of Rheumatic Diseases|January 23, 2025
Case Series: The Challenge of Using Immune Checkpoint Inhibitors in Anti-Transcriptional Intermediary Factor 1 <math> </math> Antibody-Positive DermatomyositisLiang Chen, Sabrina Fallavollita, Lama Sakr, et al.
Gynecologic Oncology|November 23, 2005
Insulin-like growth factor receptor I targeting in epithelial ovarian cancerWalter H Gotlieb, Ilan Bruchim, Jing Gu, et al.
Frontiers in Oncology|March 26, 2021
Pre- and Postoperative Circulating IGF-I, IGFBP-3, and IGFBP-7 Levels in Relation to Endocrine Treatment and Breast Cancer Recurrence: A Nested Case-Control StudyAnn H Rosendahl, Sofie Björner, Maria Ygland Rödström, et al.
Hormones & Cancer|July 16, 2011
Circulating insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 levels and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohortCatherine Schairer, Catherine A McCarty, Claudine Isaacs, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 16, 2005
Centralized blood processing for the selenium and vitamin E cancer prevention trial: effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viabilityAlan R Kristal, Irena B King, Demetrius Albanes, et al.
Pageof 18

Showing results (61-70 of 175) with videos related to

Sort By:
Pageof 18
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 10, 2010
Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective studyLorelei A Mucci, Jennifer R Stark, Michael N Pollak, et al.
Breast Cancer Research and Treatment|October 23, 2012
Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, growth hormone, and mammographic density in the Nurses' Health StudiesMegan S Rice, Shelley S Tworoger, Bernard A Rosner, et al.
International Journal of Cancer|May 18, 2010
Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004Katharina Nimptsch, Elizabeth A Platz, Michael N Pollak, et al.
Gynecologic Oncology|August 25, 2009
BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamideMarie-Claude Beauchamp, Ariane Knafo, Amber Yasmeen, et al.
Cancer Research|October 9, 2012
Carbon source and myc expression influence the antiproliferative actions of metforminShiva Javeshghani, Mahvash Zakikhani, Shane Austin, et al.
International Journal of Rheumatic Diseases|January 23, 2025
Case Series: The Challenge of Using Immune Checkpoint Inhibitors in Anti-Transcriptional Intermediary Factor 1 <math> </math> Antibody-Positive DermatomyositisLiang Chen, Sabrina Fallavollita, Lama Sakr, et al.
Gynecologic Oncology|November 23, 2005
Insulin-like growth factor receptor I targeting in epithelial ovarian cancerWalter H Gotlieb, Ilan Bruchim, Jing Gu, et al.
Frontiers in Oncology|March 26, 2021
Pre- and Postoperative Circulating IGF-I, IGFBP-3, and IGFBP-7 Levels in Relation to Endocrine Treatment and Breast Cancer Recurrence: A Nested Case-Control StudyAnn H Rosendahl, Sofie Björner, Maria Ygland Rödström, et al.
Hormones & Cancer|July 16, 2011
Circulating insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 levels and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohortCatherine Schairer, Catherine A McCarty, Claudine Isaacs, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 16, 2005
Centralized blood processing for the selenium and vitamin E cancer prevention trial: effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viabilityAlan R Kristal, Irena B King, Demetrius Albanes, et al.
Pageof 18